We have the capability for the design and execution of the project with quick access to inventory for generating target molecules in a remarkably shorter time frame enabling quick biological screenings for affinities. With the target properties in mind, we deliver molecules, by applying our extensive knowledge in drug discovery and in optimizing various NCEs, improved physicochemical properties, Pharmacokinetic (PK) properties, and/or often circumventing toxicology-related concerns at different stages of discovery. This approach has always been pivotal in the design of 25-100 compound-focused libraries – customized to avoid the common pitfalls in drug discovery processes and to enhance the chance of hit identification or optimization with improved properties. Our large and selective in-house collection of acids, aldehydes, amines, phenols, boronic acids, and heterocyclic halides are carefully selected to be compatible with most of the drug discovery concepts, where we focus on a high-performance library design that can exponentially accelerate the success rate of a discovery program.
Two decades of experience
300 compounds in 2 months (across 5 different scaffolds)
Quick access to inventory
Fast turnaround time
Quick initiation of small libraries and scaffold synthesis
Mass directed purification systems for faster TAT
Parallel synthesis
Design and synthesis of partial PROTAC libraries
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
JANUARY 04, 2021
Physicochemical properties of drug forecast its ADME chance, however, the formulation development strategy or dosage form is decided based on the bioavailability, commencement and duration of therapeutic response. An ideal strategy for formulation development should consider the dose of the drug, intended route of administration, anatomical and phys...
Read MorePeptide Development and Manufacturing Peptides are short chains of amino acids that are linked by peptide bonds. Several peptides linked together are called polypeptides. A protein contains one or more polypeptides. Therefore, proteins are long chains of amino acids held together by peptide bonds. ...
Read MoreBuilt on a solid platform of development and manufacturing scientist, we enable scale up doe both upstream and downstream processes. ...
Read MoreWe are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...
Read More2021
The sulphonic acid-functionalized Wang resin (Wang-OSO3H) was explored as a polymeric and recov- erable acidic catalyst for the synthesis of isoindolo[2,1- a ]quinazoline-5,11–dione derivatives under green conditions. Thus the Wang-OSO3H ...
Read More2005
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More2005
A novel unprecedented approach for the synthesis of various quinazolinones and dihydroquinazolinones has been using [(n-Bu3Sn)2MO4]n as a catalyst. The reaction has been screened ...
Read MoreYou are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market